Sentences with phrase «by haemophilia»

The man's brother was almost bedridden by haemophilia, but the soldier's symptoms were so mild that he did not even realize that he had the disease until he was shot on the battlefield.

Biopharmaceutical treatments, led by haemophilia, make up around 20 percent of Novo's sales, with diabetes and obesity products accounting for the remaining 80 percent.

Not exact matches

Existing haemophilia treatments tip the balance towards clotting by adding what the body lacks — the clotting factor that is missing or defective.

Indeed, exposure of the protein produced by the nanoparticle - based gene therapy to the gut mucosa prevents inhibitor development and restores clotting - factor activity in mouse models of both haemophilia A and B. «This approach really could hold big benefit for patients,» says Jörg Schüttrumpf, a transfusion - medicine specialist who led one of the studies performed at the German Red Cross Blood Donor Service in Frankfurt.

Depending on the person, the amount of factor VIII — the protein missing in haemophilia A — in the bloodstream drops by half in a mere 8 — 12 hours.

Unfortunately, haemophilia A, which is caused by factor VIII deficiency, is about four times as common as haemophilia B.

Disorders like haemophilia that are caused by faults on the X chromosome are therefore more common in males.

For all the advantages of these extended - life molecules, the researchers predict that they will be supplanted in perhaps a decade by advances in gene therapy, which will enable people with haemophilia to produce their own clotting factors.

Replacing the clotting ability lacking in haemophilia has been the treatment since the 1840s, when attempts were made to treat people with the disease by transfusion with whole blood from people with normal clotting.

A «cure» for haemophilia is one step closer, following results published in the New England Journal of Medcine of a groundbreaking gene therapy trial led by the NHS in London.

Almost exactly a year ago, we reported on a gene therapy for haemophilia that was in development by the Children's Hospital of Philadelphia (and subsequently the CHOP spinout Spark Therapeutics).

The therapy hoped to resolve some of the problems surrounding haemophilia treatment by exchanging the continual infusions for a single vector infusion that could permanently boost Factor IX expression.

Some concerns had been raised that by infusing patients with such a high activity gene, the treatment would overcorrect for haemophilia and give rise to thrombosis.

Another noteworthy issue is that psychological or psychiatric conditions are reported by 47 % of PWH, with 29 % relating these symptoms to haemophilia.4 This is even more relevant considering that psychological factors can influence both pain experience and QoL in PWH.12 Interestingly, Cassis et al 6 state that variations in QoL are better explained by psychosocial, rather than clinical predictors.